The global Inherited Metabolic Disorder market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The USA market for Global Inherited Metabolic Disorder market is estimated to increase from USD million in 2023 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The China market for Global Inherited Metabolic Disorder market is estimated to increase from USD million in 2023 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The Europe market for Global Inherited Metabolic Disorder market is estimated to increase from USD million in 2023 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
Enzyme Replacement Therapy Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Inherited Metabolic Disorder include Mayo Clinic, Angeion Corporation, Abbott U.S., Admera Health, Promega Corporation, Alomone Labs, Bio-Rad Laboratories, Novartis AG and AstaReal, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Inherited Metabolic Disorder, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inherited Metabolic Disorder. This report contains market size and forecasts of Inherited Metabolic Disorder in global, including the following market information:
Global Inherited Metabolic Disorder Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Inherited Metabolic Disorder companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Inherited Metabolic Disorder Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global Inherited Metabolic Disorder Market Segment Percentages, by Type, 2023 (%)
- Enzyme Replacement Therapy
- Cellular Transplantation
- Small Molecule Based Therapy
- Substrate Reduction Therapy
- Gene Therapy
- Drug Therapy
- Others
Global Inherited Metabolic Disorder Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global Inherited Metabolic Disorder Market Segment Percentages, by Application, 2023 (%)
- Hurler Syndrome
- Niemann-Pick Disease
- Tay-Sachs Disease
- Gaucher Disease
- Fabry Disease
- Krabbe Disease
- Others
Global Inherited Metabolic Disorder Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global Inherited Metabolic Disorder Market Segment Percentages, By Region and Country, 2023 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Inherited Metabolic Disorder revenues in global market, 2019-2024 (estimated), ($ millions)
- Key companies Inherited Metabolic Disorder revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Mayo Clinic
- Angeion Corporation
- Abbott U.S.
- Admera Health
- Promega Corporation
- Alomone Labs
- Bio-Rad Laboratories
- Novartis AG
- AstaReal
- Regeneron Pharmaceuticals
- Biophytis
- AbbVie
- Danone
- Pfizer
- Bristol Myers Squibb
- Biogen
- GSK plc
- Roche Holding AG
Outline of Major Chapters:
Chapter 1: Introduces the definition of Inherited Metabolic Disorder, market overview.
Chapter 2: Global Inherited Metabolic Disorder market size in revenue.
Chapter 3: Detailed analysis of Inherited Metabolic Disorder company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Inherited Metabolic Disorder in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
